Canada’s regulatory approach to drugs for rare diseases: our role in bringing drugs to patients

Canada’s regulatory approach to drugs for rare diseases: our role in bringing drugs to patients Canada’s health care system is complex and involves the participation of multiple stakeholders, who all have distinct roles in the planning and delivery of healthcare services. Health Canada’s decision-making role in approving a drug for marketing is distinct from the roles of those who make decisions about price-setting and public drug plan reimbursements. 2023-12-02 Health Canada open-ouvert@tbs-sct.gc.ca Health and SafetyCanada’s regulatory approachdrugs for rare-diseasesour-role in-bringing drugs-to-patients Canada’s regulatory approach to drugs for rare diseases: our role in bringing drugs to patientsHTML https://www.canada.ca/en/health-canada/services/licences-authorizations-registrations-drug-health-products/regulatory-approach-drugs-rare-diseases/our-role.html Canada’s regulatory approach to drugs for rare diseases: our role in bringing drugs to patientsHTML https://www.canada.ca/fr/sante-canada/services/licences-autorisation-et-enregistrement-medicaments-et-produits-sante/approche-canada-reglementation-medicaments-maladies-rares/notre-role.html

Canada’s health care system is complex and involves the participation of multiple stakeholders, who all have distinct roles in the planning and delivery of healthcare services. Health Canada’s decision-making role in approving a drug for marketing is distinct from the roles of those who make decisions about price-setting and public drug plan reimbursements.

Data and Resources

Similar records